Entering text into the input field will update the search result below

IRIDEX's (IRIX) CEO William Moore on Q3 2017 Results - Earnings Call Transcript

Nov. 02, 2017 10:10 PM ETIRIDEX Corporation (IRIX)
SA Transcripts profile picture
SA Transcripts

IRIDEX Corporation (NASDAQ:IRIX) Q3 2017 Earnings Conference Call November 2, 2017 5:00 PM ET


Leigh Salvo – Investor Relations

William Moore – Chief Executive Officer

Atabak Mokari – Chief Financial Officer


David Solomon – ROTH Capital


Good day, ladies and gentlemen, and welcome to the Q3 2017 IRIDEX Earnings Conference Call. [Operator Instructions]

As a reminder, this call may be recorded. I would now like to introduce your host for today's conference, Ms. Leigh Salvo Investor Relations. Ma'am, you may begin.

Leigh Salvo

Thank you, Candice. And thank you all for participating in today's call. Joining me are William Moore, CEO; and Atabak Mokari, CFO.

Earlier today, IRIDEX released financial results for the quarter and nine months ended September 30, 2017. A copy of the press release is available on the Company's website. Before we begin, I'd like to remind you that management will make statements during this call that includes forward-looking statements within the meaning of the federal securities laws, which are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995.

Any statements contained in this call that are not statements of historical fact, including statements concerning the amount and timing of revenue and Cyclo G6 unit and disposable sales and shipments, the development of our sales and marketing model medical, medical retina and surgical retina projections, timing and benefits of our Cyclo G6 product initiatives, future sales and product launch activities, future operating expenses, changes in personnel, product development and intellectual property-related matters, the adoption and effect of the Company products on its results, the market in which the Company operates, usage and efficacy of the Company's products, the Company's future financial results, our clinical study plans and the Company's strategic plans and objectives should be deemed to be forward-looking statements.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.